La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Tandem Diabetes Care Croissance future
Future contrôle des critères 1/6
Tandem Diabetes Care devrait augmenter ses bénéfices et son chiffre d'affaires de 52.5% et de 10.6% par an respectivement. Le BPA devrait croître de de 53.5% par an. Le rendement des capitaux propres devrait être -0.6% dans 3 ans.
Informations clés
52.5%
Taux de croissance des bénéfices
53.5%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 17.7% |
| Taux de croissance des recettes | 10.6% |
| Rendement futur des capitaux propres | -0.8% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 22 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
Tandem Diabetes: Mobi's Surprise Sales Fail To Offset Flat Operating Margin
Aug 14Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 04
Is It Time To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?
Jul 12Is Tandem Diabetes Care (NASDAQ:TNDM) Weighed On By Its Debt Load?
Jun 18Tandem Diabetes Care: Recent Rally Fully Deserved, Likely More Upside Here
May 29Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 26% Jump Shows Its Popularity With Investors
May 10A Look At The Fair Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
May 04At US$30.10, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely?
Mar 26Even With A 27% Surge, Cautious Investors Are Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely
Mar 08Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?
Feb 22Estimating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
Jan 14Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Rockets 63% But Many Are Still Ignoring The Company
Dec 27Is It Too Late To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?
Nov 12Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 53% Above Its Share Price
Oct 06Does Tandem Diabetes Care (NASDAQ:TNDM) Have A Healthy Balance Sheet?
Sep 17Should You Think About Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Now?
Aug 08Calculating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
Jul 03Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt Sensibly?
Jun 13Cautious Investors Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely
May 06Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?
Jan 04Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Potentially Undervalued?
Oct 15Tandem Diabetes Care: Overpriced, Underdelivering
Sep 22An Intrinsic Calculation For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Suggests It's 50% Undervalued
Sep 10Tandem Diabetes stock falls 10% on disappointing Q2 result
Aug 03Tandem Diabetes Care acquires Capillary Biomedical; terms undisclosed
Jul 21Tandem Diabetes Care: Strong Financials And Revenue, Overpenalized For Missed Earnings
Jul 08Tandem Diabetes Care (NASDAQ:TNDM) Is Looking To Continue Growing Its Returns On Capital
Jun 20Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 43% Above Its Share Price
May 30Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 1,098 | -46 | N/A | N/A | 14 |
| 12/31/2025 | 989 | -80 | -11 | N/A | 18 |
| 12/31/2024 | 890 | -116 | -19 | N/A | 18 |
| 6/30/2024 | 796 | -136 | -64 | -20 | N/A |
| 3/31/2024 | 770 | -141 | -67 | -21 | N/A |
| 12/31/2023 | 748 | -223 | -83 | -32 | N/A |
| 9/30/2023 | 771 | -208 | -49 | -19 | N/A |
| 6/30/2023 | 790 | -224 | -41 | 5 | N/A |
| 3/31/2023 | 795 | -204 | -33 | 18 | N/A |
| 12/31/2022 | 801 | -95 | 8 | 50 | N/A |
| 9/30/2022 | 791 | -68 | 21 | 64 | N/A |
| 6/30/2022 | 766 | -13 | 50 | 74 | N/A |
| 3/31/2022 | 738 | 6 | 74 | 96 | N/A |
| 12/31/2021 | 703 | 16 | 88 | 111 | N/A |
| 9/30/2021 | 661 | 22 | 85 | 107 | N/A |
| 6/30/2021 | 605 | 7 | 62 | 87 | N/A |
| 3/31/2021 | 542 | -25 | 45 | 74 | N/A |
| 12/31/2020 | 499 | -34 | -8 | 25 | N/A |
| 9/30/2020 | 439 | -49 | -6 | 29 | N/A |
| 6/30/2020 | 410 | -42 | 5 | 37 | N/A |
| 3/31/2020 | 394 | -17 | 1 | 25 | N/A |
| 12/31/2019 | 362 | -25 | 22 | 42 | N/A |
| 9/30/2019 | 330 | -24 | 23 | 37 | N/A |
| 6/30/2019 | 282 | -55 | 0 | 10 | N/A |
| 3/31/2019 | 223 | -113 | -4 | 0 | N/A |
| 12/31/2018 | 184 | -123 | -11 | -8 | N/A |
| 9/30/2018 | 148 | -138 | -38 | -34 | N/A |
| 6/30/2018 | 129 | -119 | -52 | -50 | N/A |
| 3/31/2018 | 116 | -82 | N/A | -58 | N/A |
| 12/31/2017 | 108 | -73 | N/A | -66 | N/A |
| 9/30/2017 | 96 | -76 | N/A | -68 | N/A |
| 6/30/2017 | 82 | -90 | N/A | -67 | N/A |
| 3/31/2017 | 83 | -87 | N/A | -66 | N/A |
| 12/31/2016 | 84 | -83 | N/A | -61 | N/A |
| 9/30/2016 | 84 | -81 | N/A | -58 | N/A |
| 6/30/2016 | 88 | -70 | N/A | -54 | N/A |
| 3/31/2016 | 81 | -72 | N/A | -59 | N/A |
| 12/31/2015 | 73 | -72 | N/A | -59 | N/A |
| 9/30/2015 | 62 | -79 | N/A | -62 | N/A |
| 6/30/2015 | 59 | -79 | N/A | -61 | N/A |
| 3/31/2015 | 54 | -79 | N/A | -60 | N/A |
| 12/31/2014 | 50 | -80 | N/A | -61 | N/A |
| 9/30/2014 | 42 | -85 | N/A | -61 | N/A |
| 6/30/2014 | 36 | -78 | N/A | -58 | N/A |
| 3/31/2014 | 32 | -74 | N/A | -56 | N/A |
| 12/31/2013 | 29 | -63 | N/A | -48 | N/A |
| 9/30/2013 | 21 | -48 | N/A | -45 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: TNDM devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: TNDM devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: TNDM devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de TNDM ( 10.6% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de TNDM ( 10.6% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: TNDM devrait être non rentable dans 3 ans.